TAMPA, Fla. /Florida Newswire/ — The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for victims who’re being dealt with for a C. diff. an an infection (CDI) together with these which are recovering or who’ve expert CDI recurrences. The victims, relations, and caregivers will all revenue from the information and up-to-date information provided.
Presenters are amongst among the many excessive C diff. thought leaders and embody healthcare professionals, practitioners, and educators who’re serving to to range one of the simplest ways individuals maneuver by way of a C. difficile an an infection, worldwide.
Unlike totally different shows on this topic, C. diff. Survivors will share their C. diff. an an infection journeys to produce a real-world perspective on the affected individual experience. Other issues addressed will embody making a practice for patient-centered care, C. diff. enhancements, diagnostics, evaluation, environmental safety, medical trials, and analysis, C diff. in pediatric victims and further.
To register for this world live-online event, go to: https://cdifffoundation.org/patient-family-caregiver-symposium-july-16-2021/
About Clostridioides difficile Infection (CDI)
Clostridioides (beforehand Clostridium) difficile, typically generally known as C. difficile, C. diff., is probably going some of the typical set off and principal healthcare-associated an an infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections yearly throughout the United States and is said to roughly 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on inside estimates along with a recurrence cost of roughly 20 %, the C Diff Foundation believes that the annual incidence throughout the U.S. approaches 600,000.
About Seres Therapeutics
Seres Therapeutics is a late-clinical stage biotechnology agency with a robust development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of illnesses by modulating the function of the human microbiome.
It reported optimistic, topline outcomes from the pivotal Phase Three ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile an an infection (CDI).
For further information: https://www.serestherapeutics.com/
About the C Diff Foundation
C Diff Foundation, a 501(c)(3) nonprofit, is the primary affected individual and healthcare group educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, therapies, medical trials, diagnostics, help, and environmental safety worldwide. Their Mission continues to maneuver forward and develop by way of evaluation carried out by authorities, enterprise, and academia strengthening the advocacy on behalf of victims, households, caregivers, healthcare professionals, and researchers worldwide.
For further information: https://cdifffoundation.org/
Follow C Diff Foundation:
Twitter @cdiffFoundation #cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021
C Diff Foundation(TM) is a trademark of the C Diff Foundation, established 2012 throughout the U.S.